Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on AGIO. Janney Montgomery Scott lowered Agios Pharmaceuticals from a buy rating to a neutral rating in a research note on Monday, June 26th. Leerink Swann upgraded Agios Pharmaceuticals from a market perform rating to an outperform rating and upped their price objective for the company from $50.00 to $80.00 in a research note on Wednesday. BidaskClub upgraded Agios Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, July 13th. ValuEngine upgraded Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, June 22nd. Finally, Credit Suisse Group restated an outperform rating and issued a $61.00 price objective on shares of Agios Pharmaceuticals in a research note on Tuesday, April 18th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of Buy and an average price target of $67.25.

Agios Pharmaceuticals (NASDAQ:AGIO) traded down 2.51% during mid-day trading on Wednesday, reaching $61.46. The company’s stock had a trading volume of 477,021 shares. Agios Pharmaceuticals has a 52-week low of $35.84 and a 52-week high of $67.74. The stock’s market cap is $2.96 billion. The company has a 50 day moving average of $55.14 and a 200-day moving average of $50.99.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.24. Agios Pharmaceuticals had a negative return on equity of 71.20% and a negative net margin of 491.54%. The business had revenue of $10.51 million for the quarter, compared to analyst estimates of $9.65 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. Agios Pharmaceuticals’s revenue was down 66.4% on a year-over-year basis. Equities analysts forecast that Agios Pharmaceuticals will post ($6.43) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Canaccord Genuity Reiterates “$90.00” Price Target for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/canaccord-genuity-reiterates-90-00-price-target-for-agios-pharmaceuticals-inc-nasdaqagio.html.

In other news, CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total value of $1,618,650.00. Following the transaction, the chief executive officer now owns 3,000 shares of the company’s stock, valued at $179,850. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the completion of the transaction, the director now directly owns 91,206 shares in the company, valued at approximately $4,295,802.60. The disclosure for this sale can be found here. Insiders sold 79,120 shares of company stock worth $4,557,207 in the last ninety days. 10.55% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. C WorldWide Group Holding A S purchased a new position in Agios Pharmaceuticals during the first quarter valued at approximately $105,000. Bank of Montreal Can increased its position in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares during the last quarter. Blue Sky Asset Management LLC purchased a new position in Agios Pharmaceuticals during the first quarter valued at approximately $129,000. Russell Investments Group Ltd. increased its position in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares during the last quarter. Finally, Advantage Investment Management LLC increased its position in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares during the last quarter. 84.24% of the stock is currently owned by institutional investors.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.